Clinical Efficacy And Biologic Effects Of Preoperative Portal Vein Embolization In Patients With Colorectal Liver Metastases
- Determine whether portal vein embolization results in significant hypertrophy of the
remaining liver and potentially decreases the risk of liver failure after hepatic
resection in patients with liver metastases from primary colorectal cancer.
- Determine the biologic effects of this therapy on liver metastases and normal liver
parenchyma in these patients.
OUTLINE: Patients undergo portal vein embolization with 200-300 micron polyvinyl chloride
particles suspended in Iohexol 300. Approximately 3-6 weeks after embolization, patients
undergo an exploratory laparotomy followed by hepatic surgical resection.
Patients are followed for at least 6 months.
PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
Primary Purpose: Treatment
Ronald DeMatteo, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center
|New York, New York 10021